



MAKE THE RIGHT CONNECTIONS

BIOTECHNOLOGY BUSINESS EXCHANGE

BBE2007 PROGRAMME

- 10.00** **Philip Kendall**, UK Trade & Investment
Introduction and overview of UK support for overseas trade
- 10.10** **John Sime**, Bioscience for Business KTN
Bioscience Networks
- 10.25** **Jan Chojecki**, IATC
Meanwhile...Down on the Farm. What's up in AgBiotech?
- 10.40** **Iain Cloughley**, UK Trade & Investment
Beyond Red Bio

Refreshments served at 09.30, 11.00 and 15.00
Buffet lunch at 12.30

1:1 Partnering meetings every half hour from 10.30 until 18.00



BioWednesday

'Innovative deal sourcing'

BY INVITATION ONLY - Separate registration is required

please contact Marjory Goodall, mgoodall@london-first.co.uk +44 (0)20 7665 1575

- 18.00** Registration & Tea/Coffee
- 18.30** Welcome - Tony Jones, Director, London Biotechnology Network
- 18.35** Welcome- Dominic Jermey, Managing Director, UK Trade & Investment Sectors Group
- 18.45** Introduction - Paul McCubbin, Head of Business Development, BTG
- 18.55** Enda Gribbon, Transaction Director, AstraZeneca
- 19.15** Oliver Boucher, Trigen
- 19.35** Closing remarks - Tony Jones, Director, London Biotechnology Network
- 19.40** Networking and drinks
- 21.00** Close

Speaker Profiles

Philip Kendall

Philip is the Senior Sector Manager in the LifeSciences Sector Team of UK Trade & Investment. He looks after the programme of international activity for the Biotech and Pharma sectors.

Dr John Sime

Currently Director of the Bioscience for Business KTN, John trained as a synthetic organic chemist at the University of Edinburgh before joining Beecham Pharmaceuticals as a medicinal chemist. During his career in pharmaceutical research he worked on biosynthetic pathway elucidation for clavulanic acid and went on to be Head of Biotransformation Research for SB. With a worldwide remit for research and development of enzyme catalysed reactions and processes, he was involved in a wide range of reactions and therapeutic areas.

For many years he was Director of Research & Development at Zylepsis, a company targeting the food and cosmetic market sectors, where a number of products were developed from the laboratory to manufacture and became traded products before joining Novacta as Business Development Director. John is a Chartered Chemist and Fellow of the Royal Society of Chemistry.

Dr Jan Chojecki

Jan Chojecki is Managing Director of Plant Bioscience Limited. PBL (www.pbltechnology.com) is an independent intellectual property management and technology development company that specializes in protecting and commercializing IP and technology emerging from public sector research institutions around the world.

PBL was established in 1994 by the John Innes Centre and The Sainsbury Laboratory, Norwich UK. In 2004, the UK's principal government funder of biological sciences, the Biotechnology and Biological Sciences Research Council, also became a shareholder. PBL proactively identifies and secures protection for emerging intellectual property in life sciences sectors, and licenses to industry for commercial exploitation. It also catalyses start-up company formation.

Prior to joining PBL in 1997, Jan led international agribusiness biotechnology R&D and product development programmes with Zeneca plc (formerly ICI Seeds and later to become Syngenta). Between 1984 and 1986 he was a post-doctoral research fellow at the Carlsberg Laboratory in Copenhagen following his PhD in plant genetics and biochemistry at the Plant Breeding Institute in Cambridge. His first degree was in Natural Sciences from the University of Cambridge.

Between 2001 and 2007 Jan was Scientific Advisor to the Cambridge Gateway Fund (a venture capital fund specializing in early stage technology companies). He is an advisor to the Research and Business Service department of the University of East Anglia, and he is a member of the Technology Transfer Advisory Board of the Danish Institute of Agricultural Sciences. He has also served on the Board of Directors of several PBL spin-out companies, including Novacta Biosystems Limited, Chameleon Biosurfaces Limited and IDNA Genetics Limited.

Dr Iain Cloughley

Iain is a specialist consultant for the UK Trade & Investment life sciences team. He also works as a consultant to biotechs, pharmaceutical companies, universities and R&D institutes.

Iain has spent the last 20 years setting up and leading start-up and spin-out companies in the biotechnology and pharma sector. He also has hands-on experience in R&D and manufacturing at Merck, Sharpe & Dohme, Dundee Biotech and Scotia Pharmaceuticals. During his career, he's negotiated a series of JVs and strategic alliances in various companies, including JSR Clover in Scotland (pig fertility and genetics), Clover Corporation in Australia (natural oils), Nu-Mega Lipids in Australia (fish oils), Cannanish in Scotland (pharmaceutical products), Efamol in England (pharmaceutical products), Alginate Industries in Scotland (pharmaceuticals from natural sea products) and the Tea Research Foundation in Malawi.

Iain is based in Northumberland, was born in Scotland and educated in Wales. He holds a degree in Chemistry & Biology and a PhD in pharmaceutical chemistry. He's published around 60 scientific papers in pharmaceutical chemistry, tea, lipids and natural products.

BioWednesday profiles will be provided at the start of the 6pm meeting.